Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VTGNVery BearishResearch Analysisnews

High materiality9/10

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Dec 17, 2025, 1:06 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The significant drop of 79.53% reflects the market's strong negative reaction to trial failure. Historically, failed trials have led to drastic declines in biotech stocks.

AI summary

What happened, with direct paths to the underlying reporting

VTGN's stock plunged 79.53% following trial failure. PALISADE-3 study did not meet primary efficacy endpoint. Company plans to seek FDA feedback on the trial results. Cash preservation measures were implemented for operational efficiency. VTGN shares are trading at a new 52-week low.

VTGN's stock plunged 79.53% following trial failure.
PALISADE-3 study did not meet primary efficacy endpoint.
Company plans to seek FDA feedback on the trial results.
Cash preservation measures were implemented for operational efficiency.
VTGN shares are trading at a new 52-week low.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Vistagen Reassesses SA Strategy After Post-Hoc Signal and FDA Pathway Talks